AVLN.US Avalyn Pharma Inc. Common Stock
- Market cap
- USD 1.34B
- P/E
- -
- P/B
- 3.40x
- ROE
- -30.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AVLN.US undervalued?
Graham numberThe Graham number of Avalyn Pharma Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Avalyn Pharma Inc. Common Stock fundamental analysis
No fundamental analysis for Avalyn Pharma Inc. Common Stock yet.
Avalyn Pharma Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmon…
Full company profileAvalyn Pharma Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Avalyn Pharma Inc. Common Stock annual financial statements
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | - |
| Operating Income | -57.1M | -91.3M | -123M |
| EBITDA | -57.1M | -91.3M | -121M |
| Net Income | -49.7M | -85.2M | -114M |
| EPS | -1.19 | -2.04 | -2.57 |
| Balance Sheet | |||
| Total Assets | 125M | 149M | 399M |
| Total Liabilities | 299M | 388M | 29.0M |
| Shareholders' Equity | -175M | -239M | 370M |
| Cash & Short-term Investments | 111M | 138M | 327M |
| Total Debt | - | 1.67M | 16.9M |
| Cash Flow | |||
| Operating Cash Flow | -48.4M | -81.5M | -110M |
| Capital Expenditure | 95.0K | 344K | 879K |
| Free Cash Flow | -48.5M | -81.8M | -111M |
| Ratios | |||
| ROE | - | - | -30.8% |
| ROA | -39.9% | -57.2% | -28.5% |
| Debt to Equity | - | - | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Avalyn Pharma Inc. Common Stock dividends
Avalyn Pharma Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Avalyn Pharma Inc. Common Stock
- Insiders 0.00%
- Institutions 100.00%
- Public & others 0.00%
- Shares outstanding 44.3M
- Free float 27.4M
Top funds holding AVLN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 1.38M | 3.10% | -93.28% | Jun 2026 |
| Fidelity Small Cap Growth | 1.23M | 2.78% | 0.00% | Aug 2026 |
| T. Rowe Price Health Sciences | 921K | 2.08% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 627K | 1.41% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 534K | 1.21% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 454K | 1.02% | 0.00% | Oct 2026 |
| T. Rowe Price Small-Cap Stock | 450K | 1.01% | +5.38% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 386K | 0.87% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 332K | 0.75% | 0.00% | Sep 2026 |
| PGIM Jennison Health Sciences Z | 318K | 0.72% | 0.00% | Sep 2026 |
| Fidelity Blue Chip Growth | 281K | 0.63% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 271K | 0.61% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 269K | 0.61% | -11.03% | Sep 2026 |
| Fidelity Growth Company Fund | 267K | 0.60% | 0.00% | Aug 2026 |
| T. Rowe Price Instl Small-Cap Stock | 242K | 0.55% | +6.61% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 211K | 0.48% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 187K | 0.42% | 0.00% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 162K | 0.37% | 0.00% | Sep 2026 |
| Federated Hermes Kaufmann Small Cap A | 160K | 0.36% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 139K | 0.31% | +2.88% | Oct 2026 |
Top institutions holding AVLN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 5.84M | 13.16% | 0.00% | Jun 2026 |
| Novo A/S | 3.88M | 8.76% | 0.00% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 3.31M | 7.46% | 0.00% | Jun 2026 |
| Perceptive Advisors LLC | 2.68M | 6.03% | 0.00% | Jun 2026 |
| Suvretta Capital Management, LLC | 2.50M | 5.65% | 0.00% | Jun 2026 |
| NVP Associates LLC | 2.27M | 5.12% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 2.20M | 4.97% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.74M | 3.91% | 0.00% | Jun 2026 |
| Catalio Capital Management, LP | 1.68M | 3.78% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 1.60M | 3.62% | 0.00% | Jun 2026 |
| Eventide Asset Management, LLC | 1.38M | 3.10% | 0.00% | Jun 2026 |
| Bellevue Group AG | 1.35M | 3.05% | 0.00% | Jun 2026 |
| BlackRock Inc | 977K | 2.20% | 0.00% | Jun 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC | 967K | 2.18% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 959K | 2.16% | 0.00% | Jun 2026 |
| Andera Partners | 930K | 2.10% | 0.00% | Jun 2026 |
| Jennison Associates LLC | 813K | 1.83% | 0.00% | Jun 2026 |
| BRAIDWELL LP | 801K | 1.81% | 0.00% | Jun 2026 |
| TPG GP A, LLC | 773K | 1.74% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 740K | 1.67% | 0.00% | Jun 2026 |
Avalyn Pharma Inc. Common Stock company profile
- Company name
- Avalyn Pharma Inc. Common Stock
- Ticker
- AVLN.US
- Exchange
- USA Stocks
- Listed since
- Apr 30, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Fiscal year end
- December
- Address
- 105 W First Street, Boston, MA, United States, 02127
- Phone
- (206) 707-0340
- Website
- avalynpharma.com
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
Avalyn Pharma Inc. Common Stock management
10- Ms. Lyn BaranowskiCEO, President & Director · born 1976
- Mr. Douglas R. CarlsonCFO & Chief Business Officer · born 1979
- Dr. Melissa Rhodes DABT, Ph.D.Chief Operating Officer · born 1978
- Dr. Howard M. Lazarus M.D.Chief Medical Officer · born 1966
- Ms. Cassie SaitowSenior Director of IR & Corporate Communications
- Mr. Adam H, Golden J.D.General Counsel & Head of Business Development · born 1964
- Dr. Craig Conoscenti M.D.Senior Vice President of Clinical Development
- Mr. James BishopSenior Vice President of Business Operations
- Dr. Stephen Pham Ph.D.Senior Vice President of Product Development
- Ms. Jill DenningSenior Vice President of Clinical Development Operations